Calithera Biosciences
Operating Status: Closed
Calithera Biosciences, a US-based company, develops novel drugs for cancer treatment targeting tumor metabolism and immunology.
Calithera Biosciences, a US-based company, develops novel drugs for cancer treatment targeting tumor metabolism and immunology.
Calithera Biosciences, founded in South San Francisco, was dedicated to developing novel small molecule drugs aimed at targeting tumor metabolism and immunology for cancer treatment. The company's core mission was to discover and advance innovative therapies that could significantly improve the lives of cancer patients. Calithera's product pipeline focused on addressing unmet medical needs in oncology by leveraging their expertise in tumor biology and immune modulation.
Notable figures associated with Calithera included a team of experienced scientists and executives with backgrounds in pharmaceutical development and oncology research. The company attracted significant investment from venture capital firms specializing in biotech innovations. Key achievements included advancing several drug candidates into clinical trials, demonstrating potential efficacy in treating various cancer types. Although Calithera has since ceased operations, its contributions to cancer research and drug development have had a lasting impact on the field.
Companies similar to Calithera Biosciences include Ideaya Biosciences, Mateon Therapeutics, Sutro Biopharma and Chimera Bioengineering.
Calithera Biosciences was founded in 2010.
Calithera Biosciences' headquarters is located in South San Francisco, CA, US.
Calithera Biosciences' most recent funding round was for $10M (USD) in March 2022.
As of Mar 30, 2022, Calithera Biosciences has disclosed funding of $341.4M (USD). Undisclosed round amounts are excluded.
Chimera Bioengineering
chimera.bio
